Kozłowski Mateusz, Borzyszkowska Dominika, Golara Anna, Lubikowski Jerzy, Cymbaluk-Płoska Aneta
Department of Reconstructive Surgery and Gynecological Oncology, Pomeranian Medical University in Szczecin, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.
Int J Mol Sci. 2025 Apr 5;26(7):3413. doi: 10.3390/ijms26073413.
Ovarian cancer (OC) is one of the most common cancers in women. Biomarkers for OC are still being sought. The aim of this review was to evaluate microRNAs in the prognosis and diagnosis of OC. We conducted a literature review searching for articles published from January 2014 to September 2024. We included articles presenting the association of microRNAs with ovarian cancer prognosis, where patient survival was shown by the Kaplan-Meier curve, and articles presenting the association of microRNAs with ovarian cancer diagnosis, where the results were presented as an ROC curve. MicroRNAs are promising clinical markers in ovarian cancer patients. As is shown here, expression (high or low) of various miRNAs was differentially associated with survival in OC patients, with some miRNAs being associated with a longer survival and some with a shorter survival. In the absence of diagnostic markers for OC, the raised role of miRNAs in diagnosis seems all the more important. The diagnostic value of miRNAs has been shown, mostly as blood biomarkers, although they have also been evaluated as tissue or urine markers. MiRNAs have an important role as clinical biomarkers for ovarian cancer, not only as single molecules, but also as biomarker pairs or panels of miRNAs. It should be noted that most of the miRNAs reviewed here have been studied once, so despite the promising results, it seems necessary to conduct studies to confirm or negate the results obtained.
卵巢癌（OC）是女性最常见的癌症之一。目前仍在寻找卵巢癌的生物标志物。本综述的目的是评估微小RNA在卵巢癌预后和诊断中的作用。我们进行了一项文献综述，搜索了2014年1月至2024年9月发表的文章。我们纳入了展示微小RNA与卵巢癌预后关联的文章（其中患者生存率通过Kaplan-Meier曲线显示），以及展示微小RNA与卵巢癌诊断关联的文章（其中结果以ROC曲线呈现）。微小RNA是卵巢癌患者中有前景的临床标志物。如此处所示，各种微小RNA的表达（高或低）与卵巢癌患者的生存率存在差异关联，一些微小RNA与较长生存期相关，一些则与较短生存期相关。在缺乏卵巢癌诊断标志物的情况下，微小RNA在诊断中的重要作用显得更为突出。微小RNA的诊断价值已得到证实，主要作为血液生物标志物，不过它们也被评估为组织或尿液标志物。微小RNA作为卵巢癌的临床生物标志物具有重要作用，不仅作为单个分子，还作为微小RNA对或微小RNA panel。应当指出的是，此处综述的大多数微小RNA仅被研究过一次，所以尽管结果很有前景，但似乎仍有必要开展研究以证实或否定所得结果。
